These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 35028304)

  • 1. Repurposing of Drugs for SARS-CoV-2 Using Inverse Docking Fingerprints.
    Jukič M; Kores K; Janežič D; Bren U
    Front Chem; 2021; 9():757826. PubMed ID: 35028304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based virtual screening of phytochemicals and repurposing of FDA approved antiviral drugs unravels lead molecules as potential inhibitors of coronavirus 3C-like protease enzyme.
    Bahadur Gurung A; Ajmal Ali M; Lee J; Abul Farah M; Mashay Al-Anazi K
    J King Saud Univ Sci; 2020 Sep; 32(6):2845-2853. PubMed ID: 32837113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Strategies of Antiviral Drug Discovery for COVID-19.
    Mei M; Tan X
    Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multi-stage virtual screening of FDA-approved drugs reveals potential inhibitors of SARS-CoV-2 main protease.
    Mandour YM; Zlotos DP; Alaraby Salem M
    J Biomol Struct Dyn; 2022 Mar; 40(5):2327-2338. PubMed ID: 33094680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug repurposing studies targeting SARS-CoV-2: an ensemble docking approach on drug target 3C-like protease (3CL
    Koulgi S; Jani V; Uppuladinne M; Sonavane U; Nath AK; Darbari H; Joshi R
    J Biomol Struct Dyn; 2021 Sep; 39(15):5735-5755. PubMed ID: 32679006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
    Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
    Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential Inhibitors for Novel Coronavirus Protease Identified by Virtual Screening of 606 Million Compounds.
    Fischer A; Sellner M; Neranjan S; Smieško M; Lill MA
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32455534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2
    Khan SA; Zia K; Ashraf S; Uddin R; Ul-Haq Z
    J Biomol Struct Dyn; 2021 Apr; 39(7):2607-2616. PubMed ID: 32238094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TAT-peptide conjugated repurposing drug against SARS-CoV-2 main protease (3CLpro): Potential therapeutic intervention to combat COVID-19.
    Ansari MA; Jamal QMS; Rehman S; Almatroudi A; Alzohairy MA; Alomary MN; Tripathi T; Alharbi AH; Adil SF; Khan M; Shaheer Malik M
    Arab J Chem; 2020 Nov; 13(11):8069-8079. PubMed ID: 34909057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Potential Inhibitors of 3CL Protease of SARS-CoV-2 From ZINC Database by Molecular Docking-Based Virtual Screening.
    Abdusalam AAA; Murugaiyah V
    Front Mol Biosci; 2020; 7():603037. PubMed ID: 33392261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repurposing approved drugs as potential inhibitors of 3CL-protease of SARS-CoV-2: Virtual screening and structure based drug design.
    Meyer-Almes FJ
    Comput Biol Chem; 2020 Oct; 88():107351. PubMed ID: 32769050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CL
    Gyebi GA; Ogunro OB; Adegunloye AP; Ogunyemi OM; Afolabi SO
    J Biomol Struct Dyn; 2021 Jun; 39(9):3396-3408. PubMed ID: 32367767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational modeling of the bat HKU4 coronavirus 3CL
    Abuhammad A; Al-Aqtash RA; Anson BJ; Mesecar AD; Taha MO
    J Mol Recognit; 2017 Nov; 30(11):. PubMed ID: 28608547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual targeting of 3CL
    Rajpoot S; Alagumuthu M; Baig MS
    Curr Res Struct Biol; 2021; 3():9-18. PubMed ID: 33319212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High Throughput Virtual Screening to Discover Inhibitors of the Main Protease of the Coronavirus SARS-CoV-2.
    Olubiyi OO; Olagunju M; Keutmann M; Loschwitz J; Strodel B
    Molecules; 2020 Jul; 25(14):. PubMed ID: 32668701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidimensional virtual screening approaches combined with drug repurposing to identify potential covalent inhibitors of SARS-CoV-2 3CL protease.
    Wang Y; Gao Q; Yao P; Yao Q; Zhang J
    J Biomol Struct Dyn; 2023; 41(24):15262-15285. PubMed ID: 36961210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease.
    Kandeel M; Al-Nazawi M
    Life Sci; 2020 Jun; 251():117627. PubMed ID: 32251634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.
    Akaji K; Konno H
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Sharma A; Goyal S; Yadav AK; Kumar P; Gupta L
    J Biomol Struct Dyn; 2022 Jan; 40(1):86-100. PubMed ID: 32896226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion.
    Coleman CM; Sisk JM; Mingo RM; Nelson EA; White JM; Frieman MB
    J Virol; 2016 Oct; 90(19):8924-33. PubMed ID: 27466418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.